Individuals received second-line medicines (moxifloxacin and amikacin) instead of oral anti-TB medicines during the transplantation, and continued with the original triple or quadruple anti-TB routine after recovery of hematopoietic function after transplantation. Among these 7 individuals (4 males and 3 females; median age: 38 years; range: 3046 years), the mean period of anti-TB treatment before transplantation was 3 months (range: 24.5 months). All individuals acquired engraftment, with an implantation rate of 100%. After transplantation, the mean period of anti-TB treatment was 12 months. All individuals experienced response Pyridoxal phosphate after receiving anti-TB treatment. One individual died of leukemia relapse 6 Pyridoxal phosphate months after the transplantation, but no tuberculosis infection-related death was reported. == Conclusions == Individuals with leukemia concomitant with active tuberculosis infection can be treated with hematopoietic stem cell transplantation if they receive an effective anti-TB treatment routine. The anti-TB treatment routine had no effect against hematopoietic stem cell transplantation and was well-tolerated. All post-transplanted individuals experienced no relapse of tuberculosis during the immune-suppression period. The findings in the present investigation deserve further in-depth study. MeSH Keywords:Adult Stem Cells; Leukemia, Biphenotypic, Acute; Mycobacterium Tuberculosis == Background == The immune response in individuals with leukemia is definitely significantly lower than that in the healthy population, which makes individuals more susceptible to bacterial, viral, fungal, or additional infections. With the rising incidence of tuberculosis in recent years, the number of individuals with leukemia concomitant with tuberculosis is definitely gradually growing. Researchers demonstrated the incidence of leukemia concomitant Pyridoxal phosphate with tuberculosis varies from center to center, for example,2.3% reported by Silva in Brazil [1], 2.0% reported by Al-Anazi in Saudi Arabia [2], 2.0% reported by Chen in Taiwan China [3], and 1.28.3% in China [4]. The difference in incidence can be explained from the difference in sample size and tuberculosis-endemic areas. The mechanism for increased risk of developing tuberculosis in individuals with leukemia has been analyzed by some scholars. Caver et al. [5] reported the decrease in CD4-positive cells and the percentage of CD4 + to CD8 +, relative increase in CD8 + but with practical decline in individuals with acute leukemia and bone marrow suppression in the initial check out or after chemotherapy might contribute to Pyridoxal phosphate a high incidence of tuberculosis in individuals with leukemia. Silva et al. proposed that risk factors for individuals with hematologic malignancies and concomitant tuberculosis included poor nourishment and administration of fludarabine or corticosteroids, and high-risk factors included hematologic malignancy type and treatment routine leading to significantly impaired T cell-mediated immunity (e.g., Hodgkins lymphoma, adult T-cell leukemia/lymphoma, and high-dose corticosteroids or fludarabine therapy for individuals undergoing hematopoietic stem cell transplantation or with lymphoproliferative disorders) [1]. Hematopoietic stem cell transplantation is Rabbit Polyclonal to SERPINB12 still probably one of the most effective therapies to eradicate leukemia. You will find no instances of leukemia with active tuberculosis receiving hematopoietic stem cell transplantation previously reported in the literature. In this statement, we analyzed 7 individuals with leukemia accompanying active tuberculosis who underwent hematopoietic stem cell transplantation, in order to investigate the effectiveness and security. == Material and Methods == == Individuals group == Between January 2006 and December 2012, 7 out of 65consecutive individuals who were diagnosed with leukemia concomitant with active TB in our hospital and who underwent hematopoietic stem cell transplant were included in the study. Individuals with leukemia, including acute and chronic leukemia, were diagnosed relating to FAB criteria and with concomitant tuberculosis if any of the following condition was met: chest X-ray or CT scan exposed standard pulmonary tuberculosis; individuals experienced positive TB pores and skin test; acid-fast bacilli was recognized in sputum smears.; individuals experienced fever for over 2 weeks, or experienced no response to anti-bacterial and -fungal therapy but experienced response to anti-TB therapy. == Inclusion and exclusion criteria == Patients who have been diagnosed with leukemia accompanying tuberculosis in the Pyridoxal phosphate process of the study or accompanying onset of tuberculosis in the course of leukemia treatment while undergoing hematopoietic stem cell transplantation were included, excluding those who presented with inactive pulmonary tuberculosis in the process of leukemia treatment, were diagnosed with tuberculosis before analysis of leukemia, or were diagnosed with leukemia accompanying HIV or additional malignancies. == Anti-TB routine == After the analysis of tuberculosis, individuals received standard triple (isoniazid, rifampicin, ethambutol or pyrazinamide) or quadruple anti-TB routine (isoniazid, rifampicin, pyrazinamide, streptomycin or ethambutol) at standard doses [6]. Individuals received second-line medicines (moxifloxacin and amikacin) instead of oral anti-TB medicines during the transplantation, and continued with the original triple or quadruple anti-TB routine after recovery of hematopoietic function after transplantation. All individuals signed educated consent. == Transplantation approach and conditioning.